** Shares of Telix Pharmaceuticals TLX.AX rise as much as 3.2% to a record high of A$29.610; last up 2.6%
** The biopharma co says it does not expect business to be affected by the current international trade tariffs levied by the U.S. Government
** Co currently generates most of its revenue from U.S. sales of Illuccix, its prostrate cancer diagnostic drug
** Stock climbed 19.2% in January
(Reporting by Manasi Dasa Sundeep in Bengaluru)
((Manasi.DasaSundeep@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。